(MRNS) - Earnings & Price History

MRNS: - 5.84, $144.46M, 0.30 (5.42%)

Sector: Healthcare - Industry: Biotechnology

Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat adults with refractory focal onset epileptic seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II clinical trial to treat Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to treat status epilepticus. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. The company was founded in 2003 and is based in Radnor, Pennsylvania.Key Statistics

Past MRNS reports
Earning DateTimeTitleEPS-e EPS-a ClosePrev CloseOpen Day LowDay High Gap % CFO %Change % Volume
2017-03-09BMO-0.331.61.511.551.51.652.65%3.23%5.96%1.92M
2017-03-08BMO-0.331.511.371.371.371.610.22%10.22%2.86M
2017-03-07BMO-0.331.371.371.371.321.4369.59K
2017-03-06BMO-0.331.371.331.341.311.380.75%2.24%3.01%466.80K
2016-10-28-0.43
2016-10-27-0.431.211.271.261.21.27-0.79%-3.97%-4.72%375.45K
2016-08-05-0.38
2016-08-04-0.381.491.491.471.461.51-1.34%▲1.36%292.18K
2016-08-03-0.381.491.51.51.421.5-0.67%-0.67%206.02K
2016-08-02-0.381.51.431.411.411.5-1.40%▲6.38%4.90%474.68K
2016-05-02-0.415.925.425.35.255.92-2.21%11.70%9.23%81.81K
2016-03-07-0.365.645.9565.4960.84%-6.00%-5.21%110.59K
2015-10-29-0.516.777.817.896.537.891.02%-14.20%-13.32%103.66K
2015-08-04-0.5118.0219.3819.4117.2520.720.15%▲-7.16%-7.02%97.32K

Login | Register
Saturday Aug 18, 2018   EST
Enter a Ticker:

Economic Calendar

AAII Sentiment Survey

BULL^ neut ^ BEAR

Chart

index chart
index color
SPY257.6450.500.19%41,867,194

Upgrades/Downgrades